June 25, 2018
Almost 1 in 10 Americans – men, women, and children of all ethnicities and income levels – has diabetes.1 One…
June 22, 2018
The Food and Drug Administration has approved two generic versions of an innovative drug to treat opioid addiction, increasing available treatment options for Americans fighting addiction. The move underscores a growing realization among policymakers, regulators and industry: to address the opioid crisis, innovative solutions must be readily available.
June 19, 2018
Treating asthma is not a one-size-fits-all exercise, as patients and clinicians well know. So why do some health plan policies suggest otherwise? The question drives a new policy brief from the Institute for Patient Access.
June 19, 2018
The more than 25 million Americans with asthma experience wheezing, coughing, chest tightness and shortness of breath. Their condition can…
June 15, 2018
On May 15, 2018, the Institute for Patient Access convened its inaugural Cardiovascular Health Policy Summit in Washington,…
June 14, 2018
“Not everyone can afford the medication they need,” opens a new policy brief from the Institute for Patient Access. Co-pay coupons are one source of financial support for patients. Issued by drug manufacturers, co-pay coupons reduce patients’ out-of-pocket cost. They also help patients meet their annual deductible.
June 8, 2018
Economists at the Institute for Clinical and Economic Review advise a whopping 77 percent price discount on new CFTR modulators for cystic fibrosis, according to a final evidence report. The drugs can “substantially improve patient health outcomes,” the group concedes, but their prices exceed ICER’s cost-effectiveness threshold. One manufacturer has called ICER’s analysis “a sham.”
June 6, 2018
First one drug manufacturer, then another, has reported that net prices for their medications dropped last year. And that’s good news for patients, right? Well, it all depends.
June 4, 2018
As noted in ICER’s scoping document, uncontrolled asthma is a substantial problem that, according to the Centers for Disease Control and Prevention, afflicts 38.4 percent of children with asthma and 50 percent of adults with asthma. It is not clear from the scoping document, however, that ICER will adequately incorporate into its analysis several key issues associated with uncontrolled asthma.
June 1, 2018
As the global cancer community convenes for the annual meeting of the American Society of Clinical Oncology, one question looms large: What will President Donald Trump’s blueprint to lower drug prices mean for patient access? Especially for cancer patients, who may take several medications or live on a fixed income?
